Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Lupin updates on shipment of Mirabegron ER Tablets
With this, for all our USFDA facilities, EIRs are in place
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Sun Pharma's Dadra facility receives OAI status from US FDA
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
These observations are procedural in nature and will be responded within the stipulated time
Subscribe To Our Newsletter & Stay Updated
